Streetbeat News

Stock Prices

SHOO

In the past three months, six analysts have provided ratings for Steven Madden (NASDAQ:SHOO), with all ratings being indifferent. The average 12-month price target is $42.5, slightly down from the previous $43.00. Analysts have maintained neutral or market perform ratings, with some minor adjustments in price targets. Steven Madden has shown strong financial performance with notable revenue growth, net margin, ROE, and ROA, and maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 6:01 pm

AES

Analysts have mixed ratings for AES (NYSE:AES) over the past three months, with a slight bullish trend. The average 12-month price target has increased to $22.62. Key financial metrics show strong profitability but declining revenue growth and high debt levels.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 6:01 pm

SKX

Analysts' ratings for Skechers USA (NYSE:SKX) over the last quarter show a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $71.43, reflecting a positive outlook. Key analysts have maintained or raised their ratings, with price targets ranging from $67.00 to $76.00.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 6:00 pm

EXPE

Expedia Group (NASDAQ:EXPE) has outperformed the market over the past 15 years with an average annual return of 14.01%, resulting in a $100 investment growing to $762.17. The company currently has a market capitalization of $15.10 billion.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 6:00 pm

RJF

Raymond James Financial (NYSE:RJF) has outperformed the market over the past 10 years with an average annual return of 14.57%, surpassing the market by 3.76% annually. A $1000 investment in RJF 10 years ago would be worth $3,907.44 today.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 6:00 pm

AMC

FFIE

GME

Faraday Future Intelligent Electric Inc (NASDAQ:FFIE) has seen a significant surge in its stock price, rising 33% to $2.20 per share. This comes after a 134% increase the previous day and a 52.6% rise in pre-market trading. The rally is driven by retail investor interest and social media buzz, despite the company's financial challenges and risk of delisting. The stock is trading above its 5, 20, and 50-day moving averages, but analysts caution that it may soon become overbought.

Portfolio Pulse from Surbhi Jain

May 17, 2024 | 5:59 pm

BTTR

Better Choice Company shares are trading lower after the company reported Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 17, 2024 | 5:52 pm

ABBV

BMY

Cantor Fitzgerald has initiated coverage on AbbVie Inc (NYSE:ABBV) with an Overweight rating and a price target of $200, citing the company's ability to absorb Humira biosimilar erosion and achieve modest revenue growth. The analyst expects robust growth to resume in 2025, with a high single-digit CAGR from 2024 to 2029. Additionally, Bristol-Myers Squibb Co (NYSE:BMY) is expected to bring KarXT to market before AbbVie's emraclidine, although emraclidine may have advantages in dosing frequency, safety, and efficacy.

Portfolio Pulse from Vandana Singh

May 17, 2024 | 5:47 pm

ARDX

BPMC

CYTK

INSM

IQV

MRK

MRNA

NVO

TDOC

VKTX

Today's session saw significant options activity in the healthcare sector, with notable trades involving MRK, INSM, MRNA, IQV, BPMC, ARDX, VKTX, CYTK, NVO, and TDOC. These trades, tracked by Benzinga's options activity scanner, indicate varying sentiments from bearish to bullish among large investors, or 'whales'.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 5:35 pm

TXN

Recent analysis of Texas Instruments (NASDAQ:TXN) reveals significant bullish options activity, with 66% of traders showing a positive sentiment. The stock is currently trading at $193.98, down 0.51%, with a consensus target price of $181.4 from analysts. The next earnings report is expected in 67 days.

Portfolio Pulse from Benzinga Insights

May 17, 2024 | 5:30 pm